Icure Pharm Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 293

Employees

  • Stock Symbol
  • 175250

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.17
  • (As of Friday Closing)

Icure Pharm General Information

Description

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Contact Information

Website
www.icure.co.kr
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
  • Seoul, Seocho-gu 06170
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
KRX
Corporate Office
  • 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
  • Seoul, Seocho-gu 06170
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Icure Pharm Stock Performance

As of 14-Feb-2025, Icure Pharm’s stock price is $1.17. Its current market cap is $43.8M with 37.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.17 $1.13 $1.12 - $2.51 $43.8M 37.4M 252K $0.01

Icure Pharm Financials Summary

As of 30-Sep-2024, Icure Pharm has a trailing 12-month revenue of $45M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 69,574 108,272 119,398 331,130
Revenue 45,046 43,448 45,946 56,122
EBITDA 10,342 (14,209) (22,370) (23,211)
Net Income 387 (24,032) (32,324) (33,321)
Total Assets 108,046 128,921 177,464 181,046
Total Debt 28,772 59,292 67,220 60,911
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Icure Pharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Icure Pharm‘s full profile, request access.

Request a free trial

Icure Pharm Patents

Icure Pharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2020158514-A Cataplasm agent containing ultraviolet-curable hydrogel for transdermal administration Active 11-Feb-2016
US-20190046463-A1 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Active 11-Feb-2016
EP-3415141-A1 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Pending 11-Feb-2016
US-11382868-B2 Transdermal uv-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same Active 11-Feb-2016
EP-3415141-A4 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Pending 11-Feb-2016 A61K9/703
To view Icure Pharm’s complete patent history, request access »

Icure Pharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Icure Pharm Investments & Acquisitions (2)

Icure Pharm’s most recent deal was a Merger/Acquisition with Bio Rosette for . The deal was made on 23-Dec-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bio Rosette 23-Dec-2019 Merger/Acquisition Other Commercial Products
Cosmax ICure 01-Dec-2014 Joint Venture Distributors/Wholesale
To view Icure Pharm’s complete investments and acquisitions history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Bio Rosette Seoul, South Korea 1986

Icure Pharm FAQs

  • When was Icure Pharm founded?

    Icure Pharm was founded in 2000.

  • Where is Icure Pharm headquartered?

    Icure Pharm is headquartered in Seoul, South Korea.

  • What is the size of Icure Pharm?

    Icure Pharm has 293 total employees.

  • What industry is Icure Pharm in?

    Icure Pharm’s primary industry is Drug Discovery.

  • Is Icure Pharm a private or public company?

    Icure Pharm is a Public company.

  • What is Icure Pharm’s stock symbol?

    The ticker symbol for Icure Pharm is 175250.

  • What is the current stock price of Icure Pharm?

    As of 14-Feb-2025 the stock price of Icure Pharm is $1.17.

  • What is the current market cap of Icure Pharm?

    The current market capitalization of Icure Pharm is $43.8M.

  • What is Icure Pharm’s current revenue?

    The trailing twelve month revenue for Icure Pharm is $45M.

  • What is Icure Pharm’s annual earnings per share (EPS)?

    Icure Pharm’s EPS for 12 months was $0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »